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Introduction: Interstitial lung diseases (ILDs) form a heterogeneous group of diseases with
varying degrees of inflammation and fibrosis. Epidemiological data based on the current diag-
nostic criteria are sparse.
Objectives: To characterize the incidence rate of ILDs and idiopathic pulmonary fibrosis (IPF)
in Danish patients diagnosed at a referral hospital, to evaluate disease severity and survival in
these ILD patients and to compare the use of the 2001 and 2011 guidelines to diagnosis of IPF.
Methods: Single-centre, retrospective, observational cohort study including incident patients
diagnosed with ILD at Aarhus University Hospital between 2003 and 2009. All diagnoses were
re-evaluated according to current diagnostic criteria. Disease severity in IPF was assessed using
the GAP index.
Results: The ILD incidence was 4.1 per 100,000 inhabitants/year. IPF was the most common
diagnosis (28%) followed by connective tissue disease-related ILD (14%), hypersensitivity pneu-
monitis (7%) and non-specific interstitial pneumonia (NSIP) (7%). The GAP index was a strong
predictor of survival in IPF. Twenty-three patients who had IPF based on the 2001 criteria
had a “possible UIP” HRCT pattern but no lung biopsy, and IPF could therefore not be diag-
nosed based on the 2011 criteria.
Conclusion: ILD and IPF incidence was 4.1 and 1.3 per 100,000 inhabitants/year. The diagnostic
re-evaluation raised the number of IPF diagnoses, but a diagnostic “grey zone” was still
evident in patients with UIP features not qualifying the patients to be diagnosed with IPF.
The GAP index was valuable as a measure of IPF severity in this cohort.
ª 2013 Elsevier Ltd. All rights reserved.of Respiratory Medicine and Allergology, Nørrebrogade 44, Aarhus University Hospital, 8000 Aarhus C,
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794 C. Hyldgaard et al.Background performed HRCT scans. We did not include sarcoidosis,Interstitial lung diseases (ILDs) form a heterogeneous group
of rare diseases characterized by varying degrees of pul-
monary inflammation and fibrosis. The majority of the cases
are idiopathic, but ILDs may be caused by many exogenous
factors, such as connective tissue diseases, organic dust
and certain drugs.
Since 2001, the idiopathic interstitial pneumonias (IIPs)
have been classified in seven different entities according to
the American Thoracic Society/European Respiratory Society
(ATS/ERS) Multidisciplinary International Consensus Classifi-
cation of the IIPs [1]. This consensus has heightened the
clinical relevance of disease classification and is of major
importance in epidemiological studies of ILDs. In 2011, the
ATS/ERS/Japanese Respiratory Society (JRS)/Latin American
Thoracic Association (ALAT) guidelines of idiopathic pulmo-
naryfibrosis (IPF) [2] redefined IPFand introducedadiagnostic
algorithm that made surgical lung biopsy unnecessary in pa-
tients with a definite, usual interstitial pneumonia pattern
(UIP) on high-resolution computed tomography (HRCT).
The true incidence of the ILDs is unknown, but previous
European studies have reported incidences between 4.6
and 7.6 per 100,000 inhabitants/year [3e8]. A US study
reported incidences of 31.5 per 100,000 among men and
26.1 per 100,000 among women [9]. In all studies, IPF and
sarcoidosis were the most frequent diagnoses.
Focussing only on IPF, the reported incidence in theUSAhas
been estimated at 6.8e17.4 per 100,000 inhabitants/year
depending on the criteria used [10,11]. In the UK, an IPF inci-
dence of 4.6 per 100,000 inhabitants/year has been reported
[12], and the incidenceappears toberisingby5%per year [13].
Incidence data on other IIPs are sparse. To the authors’
knowledge, only one previous study [8] reports incidences of
non-IPF idiopathic ILDs according to the 2001 guidelines.
The aims of the present study are
(1) to investigate the incidence of ILDs including IPF in the
Central Denmark region
(2) to describe the severity of IPF using the GAP index
(3) to compare IPF diagnoses based on the 2001 ATS/ERS
criteria and the 2011 ATS/ERS/JRS/ALAT criteria.
Additionally, this study describes the use of
bronchoalveolar lavage (BAL) and video-assisted thoraco-
scopic surgery (VATS) in this cohort and how they contribute
to ILD diagnostics.
Methods
Study design and patients
This was a single-centre, retrospective, observational
cohort study including all incident patients who were
diagnosed with ILDs other than sarcoidosis and who paid a
first visit to the Department of Respiratory Diseases, Aarhus
University Hospital, between 1 April 2003 and 1 April 2009.
Patients were followed until 15 November 2009. The
department is one of three specialized ILD referral centres
in Denmark. The patients included were identified from ILD
diagnoses (ICD-10) in the hospital registry and from lists ofsince most sarcoidosis patients in Denmark are diagnosed
and treated at local hospitals without referral to a
specialized centre. Eligible patients were retrospectively
followed from the time of their first visit on suspicion of an
ILD until their last visit to the centre, death, trans-
plantation, or loss to follow-up. Cause-of-death informa-
tion was obtained from medical records.
The study was approved by the Danish Data Protection
Agency and The Danish National Board of Health.
Data collection and assessments
Details of all diagnostic examinations and pulmonary func-
tion tests at enrolment and throughout the follow-up period
were retrospectively registered from medical charts.
All available HRCT scans, patient histories and patho-
logical specimens used for disease evaluation were re-
evaluated according to the ATS/ERS Multidisciplinary In-
ternational Consensus Classification of the IIPs and the 2011
ATS/ERS/JRS/ALAT criteria for IPF and other standard
diagnostic criteria when available [1,2,14,15] Three radi-
ologists and two pulmonologists specialized in the evalua-
tion of ILDs were involved in the re-evaluation.
The 2011 ATS/ERS/JRS/ALAT criteria emphasize a multi-
disciplinary approach that involves pulmonologists, radiol-
ogists and pathologists to establish a confident diagnosis.
With regards to these 2011 criteria, an IPF diagnosis requires
exclusion of known causes of ILD, as well as the presence of
a UIP pattern on the HRCT and a histopathological pattern of
UIP. In the process of re-evaluation, the terms “end-stage
fibrosis” or “unclassifiable ILD” were used in cases where
the diagnostic examinations and the re-evaluation failed to
meet the 2011 criteria for IPF or any other specified subtype
of ILD. A diagnosis of “end-stage fibrosis” was used in the
presence of extensive, severe reticulation and/or honey-
combing on HRCT that did not satisfy the HRCT UIP criteria.
Furthermore, BAL differential counts, VATS (performed in
19% of these patients) or other findings suggested no
alternative diagnosis. In other indeterminate cases, the
term “unclassifiable ILD” was used.
The primary disease evaluation using the 2001 ATS/ERS
criteria was also recorded in the study database. Incidence
estimates are based on the 344 patients referred from
Aarhus Hospital’s main geographic coverage, which is the
Central Denmark Region with 1.2 million inhabitants [16].
Patients referred from other areas (n Z 87) were not
included in the incidence calculations.
In the absence of agreed criteria for classifying mild,
moderate and severe disease in IPF, we used the GAP model
[17] to assess outcome based on disease severity. The model
includes gender, age and physiology (forced vital capacity
(FVC) and diffusion capacity of the lung for carbonmonoxide
(DLco)). BALwas performed according to ATS guidelines [18].
Statistical analysis
Data are presented as mean  standard deviation (SD) or
median (range) if continuous or as frequencies if categori-
cal. Survival was evaluated using the KaplaneMeier method
and differences in survival curves were evaluated using the
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to examine the association between BAL cell counts and
time to death in IPF. Proportionality of hazards was evalu-
ated by visual inspection of logelog plots. All analyses were
performed using STATA statistical software (version 12.1;
StataCorp, College Station, Texas, USA).
Results
Demographics and disease incidence
A total of 431 incident ILD patients were included in the
study, and the median observational period was 19 months
(interquartile range (IQR) 10e36 months). The median
duration of patient reported symptoms before the first visit
to the referral centre was 13 months (IQR 6e36 months)
and the median time from the first visit until the final
diagnosis was 2 months (IQR 0.6e4 months).
The observed incidence rate of ILD was 4.1 per 100,000
inhabitants/year in the Central Denmark Region. The inci-
dence rose from 3.8 to 6.6 per 100,000/year during the six-
year observation period (2003e2009).
The estimated 2009 incidence of 6.6 per 100,000 in-
habitants/year in the Central Denmark Region corresponds
to 368 new cases/year in Denmark (5,580,000 inhabitants).
IPF was the most common diagnosis (n Z 121/431, 28%).
In IPF patients, the median duration of symptoms before the
first visit to the referral centre was 28 months (IQR 12e60
months), and the median time from the first visit until the
final diagnosis was 1.7 months (IQR 0.7e3.3 months). The
incidence of IPF was 1.3 per 100,000/year based on the
findings in this cohort. Two thirds of the IPF patients (81/
121) were referred from pulmonologists at 12 different
regional hospitals and one third (40/121) of the IPF patients
were referred directly to the ILD centre from GPs and non-
pulmonary hospital departments in the geographical area
served by Aarhus University Hospital. There was no statisti-
cally significant difference between the group referred
directly to the ILD centre and the group referred from pul-
monologists at regional hospitals in terms of age, gender,
pulmonary function and survival (age p Z 0.14, gender
pZ 0.42, DLco pZ 0.76, FVC pZ 0.26, survival pZ 0.71).
The estimated incidence of NSIP was 3.0 per million/year
and the incidence of DIP was 2.5 per million/year. De-
mographics and diagnoses are presented in Table 1.
Bronchoalveolar lavage (BAL)
71% of the patients (306/431) had a bronchoscopy with BAL
as part of their baseline examination. In 55% (169/306) of
these cases, BAL cytological analysis, differential count and
flow cytometry results were available. A specific differen-
tial cell count was made a standard part of the BAL eval-
uation in 2007. In specimens analysed before 2007, the
cytological analysis was descriptive and contained no spe-
cific cell counts. Positive BAL culture was found in 14% (43/
306). Streptococcus pneumoniae (nZ 15) and Haemophilus
influenzae (n Z 14) were the predominant pathogens.
Transbronchial biopsy (TBB) was performed in 25% of the
patients. The TBB contributed positively to the diagnosis in
four cases of hypersensitivity pneumonitis.In IPF, a BAL differential count was available in 54 pa-
tients. There was no difference in survival between IPF
patients who had a BAL differential count and those who
did not (pZ 0.34). The median eosinophil percentage in IPF
was 6%, the median lymphocyte percentage was 3% and the
median neutrophil percentage was 7%. We found no asso-
ciation between BAL cell counts and survival in IPF using
median values of eosinophil percentage, lymphocyte per-
centage and neutrophil percentage as thresholds (pZ 0.26,
p Z 0.89, p Z 0.53, respectively; 22 deaths occurred
among the 54 patients). Median lymphocyte percentages
were 7% (IQR 2e22) in NSIP and 59% (IQR 36e72) in HP.
Video-assisted thoracoscopic surgery (VATS)
VATS was performed in 40% (173/431) of the patients in the
cohort. The highest biopsy rates were seen in NSIP (87%)
and DIP (75%). In IPF, 43% (52/121) were biopsied.
The percentage of biopsy-confirmed IPF diagnoses
declined markedly from more than 90% of the patients in
2003 to less than 20% in 2009 concomitantly with the
implementation of the ATS/ERS 2001 recommendations.
The reasons for refraining from VATS were recorded in all
268 non-biopsied patients. In half of them (n Z 136), the
overall risk of the biopsy procedure was considered too high.
The 30-day mortality after VATS was 1% (nZ 2) and the 60-
day mortality was 3% (n Z 5). Two deaths occurred within
the first 30 days; one sudden and unexpected death after two
days, and one death from respiratory insufficiency after 25
days. The three deaths seen in the following 30 days occurred
due to acute exacerbation (nZ 1), persisting pneumothorax
with subsequent infection (nZ 1), and sepsis with possible
fungal infection and cerebral embolism (nZ 1).
Survival
There were 115 deaths during the observation period. The
majority (n Z 82, 71%) were respiratory deaths, and IPF
accounted for 53% (n Z 61) of all deaths in the cohort.
Mortality was markedly higher for IPF and end-stage
fibrosis than for any other diagnosis, and the survival dif-
ference between the two groups was not statistically sig-
nificant (p Z 0.9). The median survival in IPF was three
years (range 1 daye6.4 years) and in end-stage fibrosis 2.5
years (range 30 dayse3.7 years) (Fig. 1).
Survival at five years was 93.0% in HP, 73.6% in NSIP, and
48.2% in CTD-ILD. When IPF patients were stratified into
three groups based on their gender, age, FVC and DLco
according to the GAP model, a highly statistically significant
survival difference was found (p < 0.0001). One-year sur-
vival in GAP stage I was 95% and in GAP stage III 46%. Five-
year survival was 46% in GAP stage I and 9% in GAP stage III.
The results are shown in Fig. 2.
Diagnostic criteria in IPF
Comparison of 2001 ATS/ERS criteria and 2011 ATS/ERS/
JRS/ALAT criteria
Following a systematic re-evaluation based on the 2011
criteria, 121 patients were diagnosed with IPF. In 82 of
these patients, the re-evaluation confirmed the primary
Table 1 Patient characteristics at time of inclusion.











All patients 431 (100) 55 (236:195) 61.0 (14.1) 68 173 (40) 306 (71) 71.3 (22.2) 48.5 (19.0)
Idiopathic pulmonary fibrosis 121 (28) 77 (93:28) 67.4 (8.4) 81 52 (43) 93 (77) 72.0 (20.7) 42.3 (16.4)
Unclassifiable ILD 62 (14) 45 (29:33) 59.3 (14.5) 73 21 (34) 38 (61) 73.7 (22.8) 55.8 (21.4)
Connective tissue disease-
related ILDa
54 (13) 41 (22:32) 58.4 (11.9) 59 13 (24) 38 (70) 76.5 (24.5) 51.1 (15.1)
End-stage fibrosis 43 (11) 63 (27:16) 71.5 (8.0) 70 8 (19) 28 (65) 67.8 (20.7) 46.2 (23.5)
Hypersensitivity pneumonitis
n Z 32 7%
32 (7) 63 (20:12) 48.6 (14.6) 34 15 (47) 29 (94) 68.4 (18.7) 51.1 (17.1)
Non-specific interstitial
pneumonia n Z 30 7%
30 (7) 47 (14:16) 53.8 (16.0) 60 26 (87) 26 (87) 60.7 (22.5) 45.6 (14.4)
Desquamative interstitial
pneumonia n Z 20 5%
20 (5) 55 (11:9) 45.6 (13.4) 80 15 (75) 13 (65) 70.1 (19.8) 58.0 (21.9)
Drug-induced ILDb 20 (5) 50 (10:10) 68.0 (11.9) 70 1 (5) 8 (40) 64.2 (25.5) 44.5 (19.5)
Cryptogenic organizing
pneumonia
10 (3) 50 (5:5) 65.7 (14.1) 60 5 (50) 6 (60) 77.6 (25.6) 57.6 (16.9)
Histiocytosis 8 (2) 38 (3:5) 48.9 (17.4) 100 4 (50) 6 (75) 84.1 (17.5) 44.9 (18.9)
Lymphangioleiomyomatosis 4 (1) 0 (0:4) 57.4 (14.5) 25 0 (0) 0 (0) 74.5 (10.9) 39.0 (18.9)
Eosinophilic pneumonia 4 (1) 0 (0:4) 55.1 (5.5) 50 1 (25) 3 (75) 68.3 (15.8) 37 (8.5)
Respiratory bronchiolitis ILD 2 (0.5) 100 (2:0) 43.0 () 100 0 (0) 1 (50) 97.5 () 99.0 ()
Lymphocytic interstitial
pneumonia
2 (0.5) 100 (2:0) 80.0 () 100 0 (0) 2 (100) 88.0 () 49.0 ()
ILD: interstitial lung disease; BAL: bronchoalveolar lavage; FVC: forced vital capacity; DLco: diffusing capacity of the lung for carbon
monoxide.
a UIP pattern n Z 22; NSIP pattern n Z 14; unspecific pattern n Z 18.
b Nitrofurantoin-induced ILD in 12 cases.
796 C. Hyldgaard et al.diagnosis entered into the medical record. The re-
evaluation identified 39 additional patients who met the
criteria for IPF. Other causes of ILD were excluded based on
medical history and clinical examination. Serological
testing was available in 60% of the patients; primarily
antinuclear antibodies (ANA), immunoglobulin MFigure 1 Survival analysis (KaplaneMeier estimates)
comparing idiopathic pulmonary fibrosis (IPF) (n Z 121), end-
stage fibrosis (n Z 43), non-specific interstitial pneumonia
(NSIP) (n Z 30), hypersensitivity pneumonitis (n Z 32) and
connective tissue-related ILD (n Z 54).rheumatoid factor (IgM-RF) and antineutrophil cytoplasmic
antibodies (ANCA). All patients met the major and minor
criteria for IPF when diagnoses were reassessed based on
the 2001 ATS/ERS criteria (Table 2). No patients diagnosed
as having IPF developed features of connective tissue dis-
ease within the longitudinal follow-up period. The median
survival was the same (p Z 0.44) in patients who were
diagnosed with IPF primarily (n Z 82) and patients who
were diagnosed at the reassessment (n Z 39).Figure 2 Survival in IPF based on the GAP model. GAP stage I
n Z 37, GAP stage II n Z 55, GAP stage III n Z 23.
A cohort study of ILDs in central Denmark 797All 121 patients underwent an HRCT scan. In 60 cases
(50%), HRCT showed a definite UIP pattern according to the
2011 criteria. Fourteen of the 60 patients with a definite
UIP pattern on HRCT were biopsied. All biopsies showed UIP
patterns consistent with an IPF diagnosis. Sixty-one pa-
tients had possible UIP patterns on HRCT with subpleural,
basal predominance, reticular abnormality and no incon-
sistent findings, but absence of honeycombing.
Of the 61 patients with a possible UIP pattern on HRCT,
38 had a biopsy: 30 had a definite UIP pattern on histopa-
thology, seven had probable UIP and one patient had a
possible UIP pattern. The remaining 23 patients with a
possible UIP pattern on HRCT had no biopsy, but their
clinical course made IPF a likely diagnosis (Table 3).
Discussion
Main results
This study showed that IPF was the most common of the
ILDs in the Danish cohort, and the incidence of ILDs of 4.1
per 100,000 inhabitants in the Danish cohort was compa-
rable to findings in previous European studies [3e8]. The
incidence of IPF was low in this study where all IPF di-
agnoses were based on re-evaluation according to the 2011
criteria.
We found that the GAP index was useful as a measure of
disease severity in IPF and was a strong predictor of mor-
tality. Although the GAP model is previously validated in a
separate cohort, this study shows that it is useful in IPF in a
different clinical setting.Table 2 IPF diagnosis by 2001 criteria.






121 (100%) 52 (100%) 69 (100%)
Abnormal PFT 121 (100%) 52 (100%) 69 (100%)
HRCT reticulation 121 (100%) 52 (100%) 69 (100%)





BAL + TBB 13 (
11%)
BAL 45 (87%)





















121 (100%) 52/52 (100%) 69/69
(100%)
Crackles 97 (80%) 41/52 (79%) 56/69
(81%)
IPF: idiopathic pulmonary fibrosis; PFT: pulmonary function
test; HRCT: high-resolution computed tomography; BAL: bron-
choalveolar lavage; TBB: transbronchial biopsies.Incidence
ILD
The Danish Board of Health recommends that all patients
requiring diagnosis and treatment of ILD be referred to
specialized centres, and the centralization at a few public
hospitals provides excellent conditions for observational
studies. The incidence of ILD might be underestimated in
our study due to referral bias. However, we found no dif-
ference in age, gender, pulmonary function and survival
between patients referred directly from GPs or non-
respiratory departments in the geographical area served
by the Aarhus University Hospital and patients referred
from pulmonologists at regional hospitals. These findings
argue against an under-representation of older and
severely ill patients in the study.
The number of referrals to our centre rose during the
study period. In addition to the secular trend observed by
Navaratnam et al. [13], it is likely that other factors
contributed to the observed rise. Thus, access to CT scans
improved during the past decade owing to increased focus
on early detection of lung cancer. Furthermore, the period
saw a stronger GP focus on the diagnosis of chronic
obstructive pulmonary disease (COPD) and correct inter-
pretation of spirometry. These factors are likely to have
contributed to referral and diagnosis of ILD patients who
would otherwise have remained undiagnosed or mis-
diagnosed with COPD.
IPF
The observed IPF frequency of 28% is low, considering that
sarcoidosis is not included in the study. In previous studies,
IPF accounted for 40e49% of ILD patients after exclusion of
sarcoidosis [3e9], but these studies were published before
the introduction of the more specific 2011 criteria.
It has also been argued that IPF is over-diagnosed
outside the specialized centres. One study observed that
community physicians were more likely to assign a final
diagnosis of IPF than academic physicians [19]; and a
population-based study [11] found that only 10% of cases
identified by the use of diagnostic codes proved to be IPF. In
our cohort, 10% of the patients are diagnosed with end-
stage fibrosis. The majority of these patients did not un-
dergo a lung biopsy due to frailty and impaired lung func-
tion. Our study shows that survival in this group is
indistinguishable from survival in IPF, and it is likely that
many of these patients would have been diagnosed with IPF
if a full diagnostic work-up had been possible.IPF diagnostic criteria
The systematic diagnostic re-evaluation increased the
number of IPF diagnoses in this cohort and lowered the
number of patients with unclassified ILD. However, 23 pa-
tients presented a ‘possible UIP’ HRCT pattern, although no
definite IPF diagnosis could be made, because no biopsy
had been performed. These patients fulfilled the previously
used 2001 IPF criteria, but were in a diagnostic grey zone
when evaluated by the 2011 criteria. Based on careful
exclusion of differential diagnoses and evaluation of the
disease course, we chose to include these patients in the
Table 3 2011 diagnostic criteria for IPF.
798 C. Hyldgaard et al.IPF group. The mean age in this group was significantly
higher than in the group of patients from whom a biopsy
was drawn (70.3 years vs. 63.3 years). In patients older than
70 years with a possible UIP pattern on HRCT scan, Fell
et al. [20] reported a positive predictive value of 95% of a
UIP pattern on lung biopsy. These findings strongly support
the IPF diagnosis in this group of patients, and the study by
Fell et al. may be helpful in the management of patients in
the diagnostic “grey zone” that presents a considerable
challenge in clinical practice.
The fibrotic ILDs, including end-stage fibrosis and the
fibrosing idiopathic pneumonias (definite, probable and
possible IPF and fibrotic NSIP) may be seen as part of the
same disease entity.
Future revisions of the diagnostic criteria may be able to
reflect this, as our understanding of the disease process and
the prognostic determinants increases.
BAL and VATS in ILD and IPF
We found that the use of biopsies in IPF diagnostics
declined over the years following the introduction of the
2001 ATS/ERS recommendations. The biopsy complication
rate remained low with a 30-days mortality of 1% and non-
fatal complications in 13% of the cases, all of which is
comparable to current standards [21,22]. Our findings also
corroborate the recommendation against the use of TBB in
IPF diagnostics, since TBB contributed positively to diag-
nosis in HP only, and not in IPF. The role of BAL in IPF di-
agnostics remains an issue for debate. We found that
characteristic patterns of BAL inflammation contributed to
the multidisciplinary assessment in many ILD cases, and BAL
cell counts were comparable to findings in previous studies
[23,24]. Furthermore, BAL cultivation revealed bacterial
infection in 14% of the cases.In the IPF population, we investigated the correlation
between BAL cell counts and survival. We found that no
difference in survival was present based on median cell
counts of eosinophils, lymphocytes or neutrophils. Cell
counts were available in 55% of the patients who underwent
BAL. The results corroborate a previous study [25] that
showed no predictive role of eosinophil and lymphocyte
counts with respect to survival. We did not find a correla-
tion between neutrophil levels and mortality that has been
shown in the study by Kinder et al. These findings were
unchanged when we used the same cell count thresholds as
in Kinder’s study.
Severity and survival
This study illustrates the differences in prognosis among the
ILDs. It confirms that especially IPF is diagnosed at late
stages of the disease when symptoms have been present for
years and pulmonary function is severely impaired. IPF
survival in this cohort is similar to other IPF populations.
Survival in end-stage fibrosis has not been reported previ-
ously, and is indistinguishable from survival in IPF in this
cohort. We found that the combination of gender, age and
physiological parameters in the GAP index, separated the
patients with IPF into three groups with significantly
different mortality and served as a useful predictor of
survival in IPF.
Conclusion
The study of this well-characterized, population-based
cohort of Danish ILD patients presents a standardized re-
evaluation of diagnoses for all ILD subtypes and a reliable
picture of the relative distribution of ILD diagnoses. IPF is
the most frequent diagnosis and the demographic
A cohort study of ILDs in central Denmark 799characteristics of the IPF cohort are typical. The GAP index
was a valuable prognostic tool that could be used in a
clinical setting different from its derivation and primary
validation. The re-evaluation of ILD diagnoses led to fewer
unclassified cases, but the comparison of the current and
previous IPF criteria revealed a group of patients diagnosed
with IPF by the 2001 criteria who were in a grey zone when
evaluated by the 2011 criteria.
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